All facets of diabetes are a big focus of start-up and venture capital interest these days--insulin, blood-glucose testing, and new small-molecule drugs. Blood glucose monitoring is one of the few areas of in vitro diagnostics that attracts a significant amount of investor interest. Startups in this field pick one of two tacts: to try to change the testing paradigm with revolutionary technologies or to introduce incremental improvements, which could help attract big corporate partners.